Opendata, web and dolomites

NoCanTher SIGNED

Nanomedicine upscaling for early clinical phases of multimodal cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NoCanTher project word cloud

Explore the words cloud of the NoCanTher project. It provides you a very rough idea of what is the project "NoCanTher" about.

efficacy    nanoparticles    nanoformulations    pancreatic    peptide    cancer    sufficient    timeline    strategy    synthesis    nanomedicine    multigram    effect    validated    concentrate    ep2015    synergistic    formulations    vitro    scaling    preparation    milligram    mnp    spain    carry    laboratory    11    clinical    oxide    july    successfully    imdd    csa    assays    nanoformulation    patent    therapeutic    dossier    industry    multifunctional    anticancer    multifuntionalised    magnetic    translating    filed    france    quality    intracellular    ireland    academia    certified    mentioned    uk    combination    align    material    bare    hyperthermia    vivo    manufacturing    cancers    chemical    ordm    certfified    protocol    run    line    regulatory    preceding    pct    countries    status    nanotherapeutic    262943    candidates    drug    nocanther    amended       056631    iron    safety    germany    fp7    multifun    efforts    medicinal    therapy    toxicicty    stages    models    treatment    device    group    investigational    breast    participation    authorisation    sectors    plan    proven    2019    preclinical    generate    designed   

Project "NoCanTher" data sheet

The following table provides information about the project.

Coordinator
FUNDACION IMDEA NANOCIENCIA 

Organization address
address: CIUDAD UNIVERSITARIA DE CANTOBLANCO - CALLE FARADAY 9
city: MADRID
postcode: 28049
website: http://www.nanociencia.imdea.org/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.nocanther-project.eu/
 Total cost 7˙113˙778 €
 EC max contribution 7˙113˙778 € (100%)
 Programme 1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-NMP-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION IMDEA NANOCIENCIA ES (MADRID) coordinator 729˙696.00
2    BIOKERALTY RESEARCH INSTITUTE AIE ES (ARCAUTE ALAVA) participant 1˙494˙864.00
3    RESONANT CIRCUITS LIMITED UK (LONDON) participant 888˙684.00
4    Universitätsklinikum Jena DE (Jena) participant 755˙768.00
5    THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN IE (DUBLIN) participant 671˙039.00
6    FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA ES (BARCELONA) participant 630˙633.00
7    UNIVERSITE DE PARIS FR (PARIS) participant 603˙527.00
8    HOSPITAL UNIVERSITARIO DE FUENLABRADA ES (FUENLABRADA) participant 553˙624.00
9    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) participant 347˙979.00
10    IMMUPHARMA PLC UK (LONDON) participant 175˙250.00
11    CHEMICELL GMBH DE (BERLIN) participant 174˙171.00
12    FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III ES (MADRID) participant 88˙538.00
13    UNIVERSITE PARIS DIDEROT - PARIS 7 FR (PARIS) participant 0.00

Map

 Project objective

This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project.

The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer.

NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. Particularly, we plan to assess bare nanoparticles (System B) and multifunctional nanoparticles (System A) in advanced preclinical models and run a clinical study with the System B. To successfully reach this objective, we will concentrate our efforts in two main group of activities:

• Nanotherapeutic up-scaling under Certfified conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a certified production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process. • Clinical Study: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical study and the preparation of the Investigational Medicinal Device Dossier (IMDD).

This strategy will allow us to apply for Clinical Study Authorisation (CSA) then, we will carry out a Clinical Study. NoCanTher involves the participation of 11 institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).

 Deliverables

List of deliverables.
Public Web Site and Project Presentation Websites, patent fillings, videos etc. 2020-02-25 11:29:43

Take a look to the deliverables list in detail:  detailed list of NoCanTher deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Paul Southern, Quentin A. Pankhurst
Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models
published pages: 671-686, ISSN: 0265-6736, DOI: 10.1080/02656736.2017.1365953
International Journal of Hyperthermia 34/6 2020-02-25
2017 Amanda K Silva, Alba Nicolas-Boluda, Laura Fouassier, Florence Gazeau
Overcoming the tumor microenvironment: the role of nanohyperthermia
published pages: 1213-1215, ISSN: 1743-5889, DOI: 10.2217/nnm-2017-0096
Nanomedicine 12/11 2020-02-25
2017 Sandra Hallasch, Sindy Frick, Maximilian Jung, Ingrid Hilger
How gastrin-releasing peptide receptor (GRPR) and αvβ3 integrin expression reflect reorganization features of tumors after hyperthermia treatments
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-017-06100-7
Scientific Reports 7/1 2020-02-25
2017 Jelena Kolosnjaj-Tabi, Iris Marangon, Alba Nicolas-Boluda, Amanda K.A. Silva, Florence Gazeau
Nanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix
published pages: 123-137, ISSN: 1043-6618, DOI: 10.1016/j.phrs.2017.07.010
Pharmacological Research 126 2020-02-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOCANTHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOCANTHER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.2.)

nTRACK (2017)

Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration

Read More  

iNanoBIT (2017)

Integration of Nano- and Biotechnology for beta-cell and islet Transplantation

Read More  

STARSTEM (2018)

NanoSTARS imaging for STEM cell therapy for arthritic joints

Read More